AI Article Synopsis
Article Abstract
Objective: The liver acts as a frontline barrier against diverse gut-derived pathogens, and the sinusoid is the primary site of liver immune surveillance. However, little is known about liver sinusoidal immune cells in the context of chronic liver disease (CLD). Here, we investigated the antibacterial capacity of liver sinusoidal γδ T cells in patients with various CLDs.
Design: We analysed the frequency, phenotype and functions of human liver sinusoidal γδ T cells from healthy donors and recipients with CLD, including HBV-related CLD (liver cirrhosis (LC) and/or hepatocellular carcinoma (HCC)), alcoholic LC and LC or HCC of other aetiologies, by flow cytometry and RNA-sequencing using liver perfusates obtained during living donor liver transplantation. We also measured the plasma levels of D-lactate and bacterial endotoxin to evaluate bacterial translocation.
Results: The frequency of liver sinusoidal Vγ9Vδ2 T cells was reduced in patients with CLD. Immunophenotypic and transcriptomic analyses revealed that liver sinusoidal Vγ9Vδ2 T cells from patients with CLD were persistently activated and pro-apoptotic. In addition, liver sinusoidal Vγ9Vδ2 T cells from patients with CLD showed significantly decreased interferon (IFN)-γ production following stimulation with bacterial metabolites and . The antibacterial IFN-γ response of liver sinusoidal Vγ9Vδ2 T cells significantly correlated with liver function, and inversely correlated with the plasma level of D-lactate in patients with CLD. Repetitive in vitro stimulation with induced activation, apoptosis and functional impairment of liver sinusoidal Vγ9Vδ2 T cells.
Conclusion: Liver sinusoidal Vγ9Vδ2 T cells are functionally impaired in patients with CLD. Bacterial translocation and decreasing liver functions are associated with functional impairment of liver sinusoidal Vγ9Vδ2 T cells.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/gutjnl-2020-322182 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug-induced hepatic sinusoidal obstruction syndrome: current advances and future perspectives.
Arch Toxicol
December 2024
Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.
Hepatic sinusoidal obstruction syndrome (HSOS) has gained recognition as a rare form of drug-induced liver injury (DILI) in recent years. Although extensively studied in the context of hematopoietic stem cell transplantation (HSCT), the applicability of this knowledge to drug-induced HSOS remains limited due to distinct etiological factors. The primary causes of drug-induced HSOS include the ingestion of pyrrolizidine alkaloid (PA)-containing plants, as well as the use of chemotherapeutic agents and immunosuppressive drugs.
View Article and Find Full Text PDFNatural antibodies to polysaccharide capsules enable Kupffer cells to capture invading bacteria in the liver sinusoids.
J Exp Med
February 2025
School of Basic Medical Sciences, Center for Infection Biology, Tsinghua University, Beijing, China.
The interception of blood-borne bacteria in the liver defines the outcomes of invasive bacterial infections, but the mechanisms of this antibacterial immunity are not fully understood. This study shows that natural antibodies (nAbs) to capsules enable liver macrophage Kupffer cells (KCs) to rapidly capture and kill blood-borne encapsulated bacteria in mice. Affinity pulldown with serotype-10A capsular polysaccharides (CPS10A) of Streptococcus pneumoniae (Spn10A) led to the identification of CPS10A-binding nAbs in serum.
View Article and Find Full Text PDFFine-Needle Portosystemic Pressure Gradient as a Reference for Portal Hypertension in Patients with Intrahepatic Venovenous Shunt: A Prospective Study.
J Vasc Interv Radiol
December 2024
Department of Interventional Radiology, Zhongshan Hospital, Fudan University; National Clinical Research Center for Interventional Medicine, Zhongshan Hospital, Fudan University; Shanghai Institution of Medical Imaging, Fudan University. Electronic address:
Purpose: To evaluate the consistency and agreement between portal venous pressure measured by fine-needle (F), portal vein catheterization (D), and hepatic vein balloon-occlusion (W) in decompensated cirrhotic patients with intrahepatic venovenous shunts (IHVS).
Materials And Methods: 156 consecutive patients planning to receive transjugular intrahepatic portosystemic shunt in our center were screened for study participation. The F/D/W were assessed for consistency by Pearson coefficient (r), linear regression coefficient (R), and intraclass correlation coefficient (ICC), and for disagreement (error exceeding 20% of D) by Bland-Altman method.
Combination of spatial transcriptomics analysis and retrospective study reveals liver infection of SARS-COV-2 is associated with clinical outcomes of COVID-19.
EBioMedicine
December 2024
Liver Cancer Institute, Zhongshan Hospital, and Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University, Shanghai, China. Electronic address:
Background: Liver involvement is a common complication of coronavirus disease 2019 (COVID-19), especially in hospitalized patients. However, the underlying mechanisms involved are not fully understood.
Methods: Immunohistochemistry (IHC) staining of SARS-CoV-2 spike (S) and nucleocapsid (N) proteins was conducted on liver tissues from six patients with COVID-19.
Protective role of vitamin B6 on some histological changes in the liver and kidneys and measure some indicators of oxidation balance in male rats.
Cell Mol Biol (Noisy-le-grand)
November 2024
Biology Department, College of Education for Pure Sciences, University of Anbar, Iraq.
This study aimed to evaluate the therapeutic effects of B6 in rats experimentally intoxicated by benzopyrene. Twenty-eight Male Sprague Dawley (white Swiss) rats weighing 170-210 g and 3-4 months old were utilized in this examination. Rats were divided into 4 control groups (G1), B[a]P 2 pmol/μL (G2), B6 only once per 2 days for a full month at 1000 mcg (15 dose per month) (G3), B6 + B[a]P (G4).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!